du Bois Score for IPF Mortality
Predicts 1-year mortality in IPF from a single clinical visit using age, hospitalisation history, %predicted FVC, and 24-week FVC change. du Bois risk score ranges 0–100.
Score interpretation
Low risk of death within 1 year. Relatively stable disease.
→ Continue antifibrotic therapy; monitor FVC every 6 months; standard ILD care
Moderate 1-year mortality risk. Disease progression expected.
→ Optimise antifibrotic therapy; consider escalation; lung transplant evaluation; palliative care input
High risk of death within 1 year.
→ Urgent lung transplant evaluation; intensive palliative care; advance care planning discussion; symptom management
Interpretation bands for the du Bois Score. Apply clinical judgement and local guidance.
References
- du Bois RM et al. Ascertaining disease progression and treatment response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1382–1386.
Related
Curated clinical cross-links plus same-class fallbacks.
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.